Biotech Celgene refuses to stand down in battle against cancer

Just 100 years ago the average life expectancy hovered around 55 years

Bacteria, viruses, and parasites waged invisible war on our ancestors. For centuries we lost battles to plagues and pandemics, unable to fight with the tools we had. However, it was only a matter of time before human innovation turned the tide. The discovery of Penicillin in 1928 forever changed the course of medicine. Countless new vaccines for diseases ranging from the plague to tuberculosis were created.

Through the efforts of thousands of doctors and researchers, WHO announced the complete eradication of smallpox in 1980, a disease that had claimed 300 million lives in the 20th century alone. These miraculous discoveries have led to a 20 year increase in the life expectancy of humans, and sicknesses that were once a death sentence are now a simple cure.

Fantastic right? Well, this war is far from over

Now that many infectious diseases have been defeated, their more complex and complicated counterparts have come to play: non-communicable diseases. Cancer, chronic ailments, diabetes and heart disease are just a few examples of what our now older and frailer populations have to deal with. These conditions are expensive, long-lasting, and deadly; non-communicable diseases have taken 6 of the 10 spots for top causes of death around the world. There have been valiant efforts to search for an answer, and they are beginning to payoff in remissions, treatments, and new discoveries.

Unfortunately, not every country is benefiting. Millions of people across the world are not only fighting these non-communicable diseases but also face strained resources. In fact, medical treatments for cureable diseases are still unavailable to many. There simply isn’t enough supply to meet the demand.

Yet, there is hope still

But people and companies are pooling together once again, taking a definitive stand for those that can’t.

Cellgene is a biopharmaceutical company dedicated to the discovery, the development, and the commercialisation of products for the treatment of cancer and other conditions. Celgene is on a fiery path to better human health, and they have brought a new program called Celgene Cancer Care Links to the battlefield. This new program’s aim is to collaborate with local communities and institutions focused on enhancing patient care and building sustainable cancer care systems, as well as funding initiatives in under-resourced countries globally.

Celgene is just one of the many health focused companies you can put your super to work in at Zuper, with our Zuper Health option. In here you’ll find companies addressing the needs of the ageing population via the iShares Ageing Population ETF, and also innovative healthcare companies more broadly, via the iShares Healthcare Innovation ETF.

We’re Zuper excited that businesses like Celgene are trying to solve this big problem and that you can invest in them through your super. We started Zuper because we believe super can be a powerful force for change, so if you do to, we’d love you to join us.

This article is general in nature, and has been prepared without taking into account your objectives, financial situation or needs. You should consider if the information is appropriate and whether you need to speak to an accredited professional.

Han Ju Seo

3rd year Uni student from the States trying to figure out her place in the world. Deeply passionate about social impact, education, and fluffy dogs.

Share this article:
How are Zuper's investment portfolios built?
Learn how we built our Zuper super options using BlackRock's MegaTrends...